​

Spyre Therapeutics (SYRE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

SYRE Stock Forecast

Spyre Therapeutics (SYRE) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $119.89, with a high of $130.00 and a low of $107.00. This represents a 32.72% increase from the last price of $90.33.

- $30 $60 $90 $120 $150 High: $130 Avg: $119.89 Low: $107 Last Closed Price: $90.33

SYRE Stock Rating

Spyre Therapeutics stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (92.31%), 1 Hold (7.69%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 1 12 0 Strong Sell Sell Hold Buy Strong Buy

SYRE Price Target Upside V Benchmarks

TypeNameUpside
StockSpyre Therapeutics32.72%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1926
Avg Price Target$120.00$122.44$104.31
Last Closing Price$90.33$90.33$90.33
Upside/Downside32.85%35.55%15.48%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 261151--17
Sep, 26-161--17
Aug, 26-161--17
Jul, 26-17---17
Jun, 26-17---17
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 11, 2026UBS$120.00$85.6940.04%32.85%
Sep 09, 2026Colleen KusyRobert W. Baird$116.00$90.7927.77%28.42%
Aug 27, 2026Yatin SunejaGuggenheim$130.00$93.6138.87%43.92%
Aug 26, 2026Wedbush$123.00$95.1829.23%36.17%
Aug 26, 2026BTIG$121.00$107.3612.70%33.95%
Aug 26, 2026Deutsche Bank$127.00$107.3618.29%40.60%
Aug 05, 2026David NierengartenWedbush$130.00$105.8322.84%43.92%
Aug 05, 2026Robert W. Baird$120.00$104.9414.35%32.85%
Aug 05, 2026Wells Fargo$115.00$104.949.59%27.31%
Jul 13, 2026Joseph CatanzaroMizuho Securities$120.00$97.7422.77%32.85%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 20, 2026CitigroupBuyBuyhold
Oct 11, 2026UBSBuyinitialise
Aug 27, 2026GuggenheimBuyBuyhold
Aug 05, 2026WedbushOutperformOutperformhold
Aug 05, 2026Wells FargoOverweightOverweighthold
Jul 28, 2026Wolfe ResearchPeer Performdowngrade
Jun 16, 2026WedbushOutperformOutperformhold
Jun 15, 2026BTIGBuyBuyhold
Jun 04, 2026Deutsche BankBuyBuyhold
May 12, 2026Deutsche BankBuyBuyhold

Financial Forecast

EPS Forecast

$-50 $-40 $-30 $-20 $-10 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-25.02$-24.86$-46.15$-3.18$-1.98---
Avg Forecast$-24.97$-26.92$-7.51$-4.27$-3.86$-4.15$-4.74$-4.32
High Forecast$-24.97$-26.92$-7.51$-3.98$-3.05$-2.62$-2.58$-4.32
Low Forecast$-24.97$-26.92$-7.51$-4.52$-4.49$-5.66$-6.61$-4.32
Surprise %0.20%-7.65%514.51%-25.53%-48.70%---

Revenue Forecast

$0 $4M $8M $12M $16M $20M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$18.74M$2.33M$886.00K-----
Avg Forecast$18.36M$2.23M$1.12M$2.99M$4.70M$166.67K$136.21K$85.29K
High Forecast$18.36M$2.23M$1.18M$2.99M$4.70M$166.67K$136.21K$85.29K
Low Forecast$18.36M$2.23M$1.06M$2.99M$4.70M$166.67K$136.21K$85.29K
Surprise %2.05%4.42%-20.69%-----

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-65.80M$-83.81M$-338.79M$-208.02M$-155.20M---
Avg Forecast$-172.21M$-185.65M$-55.11M$-31.21M$-27.67M$-30.37M$-33.75M$-31.73M
High Forecast$-172.21M$-185.65M$-55.11M$-29.21M$-22.38M$-19.21M$-18.96M$-31.73M
Low Forecast$-172.21M$-185.65M$-55.11M$-33.21M$-32.97M$-41.53M$-48.54M$-31.73M
Surprise %-61.79%-54.85%514.76%566.46%460.83%---

SYRE Forecast FAQ

Is Spyre Therapeutics stock a buy?

Spyre Therapeutics stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Spyre Therapeutics is a favorable investment for most analysts.

What is Spyre Therapeutics's price target?

Spyre Therapeutics's price target, set by 13 Wall Street analysts, averages $119.89 over the next 12 months. The price target range spans from $107 at the low end to $130 at the high end, suggesting a potential 32.72% change from the previous closing price of $90.33.

How does Spyre Therapeutics stock forecast compare to its benchmarks?

Spyre Therapeutics's stock forecast shows a 32.72% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Spyre Therapeutics over the past three months?

  • October 2026: 5.88% Strong Buy, 88.24% Buy, 5.88% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 0% Strong Buy, 94.12% Buy, 5.88% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 0% Strong Buy, 94.12% Buy, 5.88% Hold, 0% Sell, 0% Strong Sell.

What is Spyre Therapeutics’s EPS forecast?

Spyre Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.15, marking a 109.60% increase from the reported $-1.98 in 2025. Estimates for the following years are $-4.74 in 2027, and $-4.32 in 2028.

What is Spyre Therapeutics’s revenue forecast?

Spyre Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $166.67K, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $136.21K, and $85.29K for 2028.

What is Spyre Therapeutics’s net income forecast?

Spyre Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-30.37M, representing a -80.43% decrease from the reported $-155M in 2025. Projections indicate $-33.75M in 2027, and $-31.728M in 2028.